Cambium Bio Limited
CMB
Rank in Stocks
#32545
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on... Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Share Price
$0.31737816
Last synced: 2026-10-18
Market Cap
$9.34M
Change (1 day)
0.00%
Change (1 year)
5,917.33%
Country
AU
Trade Cambium Bio Limited (CMB)
Category
Healthcare
Operating Margin for Cambium Bio Limited (CMB)
Operating Margin as of 2026 TTM: 0.00%
According to Cambium Bio Limited latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Cambium Bio Limited from 2026 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.